Submit
Search
Submit
Menu

  • Information

  • References

  • Contents

  • [1]L. Insabato, M. Del Basso De Caro, E. Caramanna, G. De Rosa: Pathology of neuroendocrine tumours. Front Biosci (Landmark Ed.)14, 4712-8 (2009)

  • [2]G.Kloppel: Oberndorfer and his successors: from carcinoid to neuroendocrine carcinoma. Endocr Pathol 18, 141-144 (2007)

  • [3]A.Gosset, P.Masson: Le tumeurs endocrines de l’appendice. Press Med 22, 237-240 (1914)

  • [4]F.Feyrter: Uber die these von den peripheren endokrinen drusen. Wien Z Innere Med Grenzgeb 10, 9-36 (1946)

  • [5]A.G.E. Pearse: The cytochemistry and ultrastructure of polypeptide hormone-producing cells of the APUD series and the embryologic, physiologic and pathologic implications of the concepts. J Histochem Cytochem 17, 303-313 (1969)

  • [6]R.Day, M.Salzet: The neuroendocrine phenotype, cellular plasticity, and the search for geneticswitches: redefining the diffuse neuroendocrine system. Neuro Endocrinol Lett 23, 379-384 (2002)

  • [7]G. Rindi, R. Arnold, FT. Bosman, C.Capella, DS. Klimstra, G. Kloppel, P. Komminoth, E.Solcia. Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: WHO classification of tumors of the digestive system. Eds: FT Bosman, F Carneiro, RH. Hruban, ND. Theise, Lyon: IARC Press (2010)

  • [8]C. Capella, E. Solcia, LH Sobin, R. Arnold. Endocrine tumours of the small intestine. In: World Health Organization Classification of Tumours. Pathology and genetics of tumours of the digestive system. Eds: SR. Hamilton, LA. Aaltonen, Lyon: IARC Press (2000)

  • [9]C. Capella, E. Solcia, LH. Sobin, R.Arnold. Endocrine tumours of the colon and rectum. In: World Health Organization Classification of Tumours. Pathology and genetics of tumours of the digestive system. Eds: SR. Hamilton, LA. Aaltonen, Lyon: IARC Press (2000)

  • [10]PU Heitz, P. Komminoth, A Perren, DS Klimstra, Y.Dayal. Pancreatic endocrine tumours: introduction. In: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Endocrine Organs. Eds: RA. DeLellis, RV. Loyd, PU. Heitz, C. Eng, Lyon: IARC Press (2004)

  • [11]G Kloppel, A Perren, PU. Heitz. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann N Y Acad Sci 1014, 13-27 (2004)

  • [12]W D. Travis. The concept of pulmonary neuroendocrine tumours. In: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Eds: WD Travis, E. Brambilla, H K. Muller-Hermelink, CC. Harris, Lyon: IARC Press (2004)

  • [13]DR. Swarts, RJ. van Suylen, MA. den Bakker, MF. van Oosterhout, FB. Thunnissen, M. Volante, AM. Dingemans, MR. Scheltinga, GP. Bootsma, HM. Pouwels, BE. van den Borne, FC. Ramaekers, EJ. Speel.Interobserver variability for the WHO classification of pulmonary carcinoids. Am J Surg Pathol 38(10), 1429-36 (2014)

  • [14]H. Sethi, M. Madanur, P. Srinivasan, B. Portmann, N. Heaton, M. Rela. Non functioning well-differentiated neuroendocrine tumor of the extrahepatic bile duct: an unusual suspect? Hepatobiliary Pancreat Dis Int 6, 549-552 (2007)

  • [15]DE. Hansel, JI Epstein, E. Berbescu, SW. Fine, RH. Young, JC. Cheville. Renal carcinoid tumor: a clinicopathologic study of 21 cases. Am J Surg Pathol 131, 1539-1544 (2007)

  • [16]M. Mascolo, V. Altieri, C. Mignogna, G. Napodano, G. De Rosa, L. Insabato. Calcitonin-producing well differentiated neuroendocrine carcinoma (carcicnoid tumor) of the urinary bladder: case report. BMC Cancer5, 88-91 (2005)

  • [17]L. Insabato, G. De Rosa, LM. Terracciano, G. Lupoli, D. Montedoro, C. Ravetto. A calcitonin-producing neuroendocrine tumor of the larynx: a case report. Tumori 79, 227-230 (1993)

  • [18]M. Capelli, G. Bertino, C. Morbini, C. Villa, S. Zorzi, M. Benazzo. Neuroendocrine carcinomas of the upper airways: a small case series with histopathological considerations. Tumori 93, 499-503 (2007)

  • [19]SR. Lakhani, IO. Ellis, SJ. Schnitt, PH. Tan, MJ. van de Vijver. WHO Classification of Tumours of the breast. Lyon: IARC (2012)

  • [20]CA. Koch, N. Azumi, MA. Furlong, RC. Jha, TE. Kehoe, CH. Trowbridge, MT. O’Dorisio, GP. Chrousos, SC. Clement. Carcinoid syndrome Caused by an Atypical Carcinoid of the Uterine cervix. J Clin Endocrinol Met 84, 4209-4213 (1999)

  • [21]Z. Bing, L. Levine, JA. Lucci, SS. Hatch, MA. Eltorky. Primary Small Cell Neuroendocrine Carcinoma of the Vagina: A Clinicopathologic Study. Arch Pathol Lab Med 128, 857-862 (2004)

  • [22]P. Dursun, MC. Salman, C. Taskiran, A. Usubutun, A. Ayhan. Primary neuroendocrine carcinoma of the fallopian tube: A case report. AM J Obst Gynecol 190, 568-571 (2004)

  • [23]K. Behnam, D. Kabus, M. Behnam. Primary ovarian undifferentiated non-small cell carcinoma, neuroendocrine type. Gynecol Oncol 92, 372-375 (2004)

  • [24]P.A. Abrahamsson. Neuroendocrine cells in tumor growth of the prostate. Endocr Relat Cancer 6, 503-519 (1999)

  • [25]M.G. Weaver, F.W. Abdul-Karin, J.R. Srigley: Paneth cell-like change and small cell carcinoma of the prostate. Two divergent forms of prostatic neuroendocrine differentiation. Am J Surg Pathol 16, 1013-1016 (1992)

  • [26]F. Abbas, F. Civanto, P. Benedetto, MS. Soloway. Small cell carcinoma of the bladder and prostate. Urology 46, 617-30 (1995).

  • [27]TL. Randolph, MB. Amin, JY. Ro, AG. Ayala. Histologic variants of adenocarcinoma and other carcinomas of prostate: pathologic criteria and clinical significance. Mod Pathol 10, 612-29 (1997)

  • [28]PA. Abrahamsson. Neuroendocrine differentiation in prostate cancer. Prostate 39, 135-48 (1999)

  • [29]H. Bonkhoff. Neuroendocrine cells in benign and malignant prostate tissue: morphogenesis, proliferation, and androgen receptor status. Prostate Suppl 8, 18-22 (1998)

  • [30]Y. Miyoshi, H. Uemura, K. Kitami, Y. Satomi, Y. Kubota, M. Hosaka. Neuroendocrine differentiated small cell carcinoma presenting as recurrent prostate cancer after androgen deprivation therapy. BJU Int 88, 982-3 (2001)

  • [31]M. Tanaka, Y. Suzuki, K. Takaoka, N. Suzuki, S. Murakami, O. Matsuzaki, J Shimazaki. Progression of prostate cancer to neuroendocrine cell tumor. Int J Urol 8, 431-436 (2001)

  • [32]CN. Papandreou, DD. Daliani, PF. Thall, SM. Tu, X. Wang, A. Reyes, P. Troncoso, CJ Logothetis.Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol 20, 3072-80 (2002).

  • [33]ME. Spieth, YG. Lin, TT. Nguyen. Diagnosing and treating small-cell carcinomas of prostatic origin. Clin Nucl Med 27, 11-7 (2002)

  • [34]IM. Modlin, MD. Shapiro, M. Kidd. An analysis of rare carcinoid tumors: clarifying these clinical conundrums.World J Surg 29, 92-101 (2005)

  • [35]C-K. Tang, C. Toker. Trabecular carcinoma of the skin. An ultrastructural study. Cancer 42, 2311-2321 (1978)

  • [36]EG. Silva, B. Mackay, H. Goepfert, MA. Burgess, RS. Fields. Endocrine carcinoma of the skin (Merkel cell carcinoma). Pathol Annu 19, 1-30 (1984)

  • [37]MP. Pulitzer, BD. Amin, KJ. Busam. Merkel cell carcinoma: review. Adv Ant Pathol 16, 135-144 (2009)

  • [38]H. Goepfert, D. Remmler, E. Silva, B. Wheeler. Merkel cell carcinoma (endocrine carcinoma of the skin) of the head and neck. Arch Otolariyngol 110, 707-712 (1984)

  • [39]H. Takenaka, S. Kishimoto, R. Shibagaki, M. Nagura, H. Yasumo. Merkel cell carcinoma with partial spontaneous regression: an immunohistochemical, ultrastructural, and TUNEL labeling study. Am J Dermatopathol 19, 614-618 (1998)

  • [40]V. Eusebi, C. Capella, A. Cossu, J. Rosai. Neuroendocrine carcinoma within lymph nodes in the absence of a primary tumor, with special reference to Merkel cell carcinoma. Am J Surg Pathol 16, 658-666 (1992)

  • [41]G. Pettinato, A. De Chiara, L. Insabato, P. Angrisani, J. Saurel, JL. Monard, V. Ruocco, F. Quarto.Neuroendocrine (Merkel Cell) Tumor of the skin: Fine-needle aspiration cytology, histology, electrn microscopi and immunohistochemistry of 12 cases. Appl Pathol 6, 17-27 (1988)

  • [42]H. Feng, M. Shuda, Y. Chang, PS. Moore. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 319, 1096-1100 (2008)

  • [43]A.Mogha, A. Fautrel, N. Mouchet, N. Guo, S. Corre, H. Adamski, E. Watier, L. Misery, MD. Galibert. Merkel cell polyomavirus small T antigen mRNA level is increased following in vivo UV-radiation. Plos one 5, Issue 7 (2010)

  • [44]AS.Moshiri, P. Nghiem. Milestones in the staging, classification, and biology of Merkel cell carcinoma.J Natl Compr Canc Netw 12, Issue 9 1255-62 (2014)

  • [45]BD.Lemos, BE. Storer, JG. Iyer, JL. Phillips, CK. Bichakjian, LC. Fang, TM. Johnson, NJ. Liegeois-Kwon, CC.Otley, KG. Paulson, MI. Ross, SS. Yu, NC. Zeitouni, DR. Byrd, VK. Sondak, JE. Gershenwald, AJ. Sober, P. Nghiem. Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system. J Am Acad Dermatol 63, Issue5, 751-61 (2010)

  • [46]RV. Lloyd. Practical markers used in the diagnosis of neuroendocrine tumors. Endocr Pathol 14, 293-301 (2003)

  • [47]K. Hiroshima, A. Iyoda, T. Shida, K. Shibuya, T. Iizasa, H. Kishi, T. Tanizawa, T. Fujisawa, Y. Nakatani. Distinction of pulmonary large cell neuroendcorine carcinoma from small cell lung carcinoma: a morphological, immunohistochemical, and molecular analysis. Mod Pathol 19, Issue 10, 1358-1368 (2006)

  • [48]S. La Rosa, E. Rigoli, S. Uccella, R. Novario, C. Capella. Prognostic and biological significance of cytokeratin 19 in pancreatic endocrine tumours. Histopathology 50, 597-606 (2007)

  • [49]A. Ali, S. Serra, SL. Asa, R. Chetty. The predictive value of of CK19 and CD99 in pancreatic endocrine tumors. Am J Surg Pathol 30, 1588-94 (2006)

  • [50]A. Goto, T. Niki, Y. Terado, J. Fukushima, M. Fukayama.Prevalence of CD99 protein expression in pancreatic endocrine tumors (PETs). Histopathology 45, 384-92 (2004)

  • [51]A. Chaudry, A. Gobl, B. Eriksson, B. Skogseid, K. Oberg. Different splice variants of CD44 are expressed in gastrinomas but not in other subtypes of endocrine pancreatic tumors. Cancer Res 54, 981-6 (1994)

  • [52]A. Rahman, A. Maitra, R. Ashfaq, CJ. Yeo, JL. Cameron, DE.Hansel.Loss of p27 nuclear expression in a prognostically favorable subset of well differentiated pancreatic endocrine neoplasms. Am J Clin Pathol 120:685-90 (2003)

  • [53]G. Pelosi, E. Bresaola, G. Bogina, F. Pasini, S. Rodella, P. Castelli, C. Iacono, G. Serio, G. Zamboni. Endocrine tumors of the pancreas: Ki67immunoreactivity on paraffin sections isan independent predictor for malignancy: a comparative study with proliferating-cell nuclear antigen and progesterone receptor protein immunostaining, mitotic index, and other clinicopathologic variables. Hum Pathol 27, 1124-34 (1996)

  • [54]M. Krausch, A. Raffel, M. Anlauf, Schott M, H. Willenberg, N. Lehwald, D. Hafner, K. Cupisti, CF. Eisenberger, WT. Knoefel. Loss of PTEN expression in neuroendocrine pancreatic tumors. Horm Metab Res. 43, 865-71 (2011)

  • [55]V. Deshpande, C. Fernandez-del Castillo, A. Muzikansky, A. Deshpande, L. Zukerberg, AL. Warshaw, GY. Lauwers. Cytokeratin 19 is a powerful predictor of survival in pancreatic endocrine tumors. Am J Surg Pathol 28:1145-53 (2004)

  • [56]G. Viale, C. Doglioni, M. Gambacorta, G. Zamboni, G. Coggi, C. Bordi. Progesterone receptor immunoreactivity in pancreatic endocrine tumors: an immunocytochemical study of 156 neuroendocrine tumors of the pancreas, gastrointestinal and respiratory tracts, and skin. Cancer 70(9), 2268–2277 (1992)

  • [57]T. Arnason, HL. Sapp, PJ. Barnes, M. Drewniak, M. Abdolell, D. Rayson. Immunohistochemical expression and prognostic value of ER, PR and HER2/neu in pancreatic and small intestinal neuroendocrine tumors. Neuroendocrinology 93(4), 249–528 (2011)

  • [58]A. Saqi, D. Alexis, F. Remotti, G. Bhagat. Usefulness of CDX2 and TTF-1 in differentiating gastrointestinal from pulmonary carcinoids. Am J Clin Pathol 123, 394-404 (2005)

  • [59]Srivastava A, Hornick J L. Immunohistochemical staining for CDX-2, PDX-1, NESP55, and TTF-1 can help distinguishing gastrointestinal carcinoid tumors from pancreatic endocrine and pulmonary carcinoids. Am J Surg Pathol 33, 626-32 (2009)

  • [60]J. Shia, LH. Tang, MR. Weiser, B. Brenner, NV. Adsay, EB. Stelow, LB. Saltz, J. Qin, R. Landmann, GD. Leonard, D. Dhall, L. Temple, JG. Guillem, PB. Paty, D. Kelsen, WD. Wong, DS. Klimstra. Is non small cell type high grade neuroendocrine carcinoma of the tubular gastrointestinal tract a distinct disease entity? Am J Surg Pathol 32, 719-31 (2008)

  • [61]W. Cheuk, MY. Kwan, S. Suster, JK. Chan. Immunostaining for thyroid transcription factor 1 and cytokeratin 20 aids the distinction of small cell carcinoma from Merkel cell carcinoma, but not pulmonary from extrapulmonary small cell carcinomas. Arch Pathol Lab Med 125, 228-31 (2001)

  • [62]IM. Jaffe, M. Rahmani, MG. Singhal, M. Younes. Expression of the intestinal transcription factor CDX2 in carcinoid tumors is a marker of midgut origin. Arch Pathol Lab Med 130, 1522-6 (2006)

  • [63]AM. Schmitt, F. Riniker, M. Anlauf, S. Schmid, A. Soltermann, H. Moch, PU. Heitz, G. Klöppel, P. Komminoth, A. Perren. Islet 1 (Isl1) expression is a reliable marker for pancreatic endocrine tumors and their metastases. Am J Surg Pathol 32, 420-5 (2008)

  • [64]J. Koo, RB. Mertens, JM. Mirocha, HL. Wang, D. Dhall. Value of Islet 1 and PAX8 in identifying metastatic neuroendocrine tumors of pancreatic origin. Mod Pathol 25, 893-901 (2012)

  • [65]PI. Lorenzo, CM. Jimenez Moreno, I. Delgado, N. Cobo-Vuilleumier, R. Meier, L. Gomez-Izquierdo, T. Berney, R. Garcia-Carbonero, A. Rojas, BR. Gauthier. Immunohistochemical assessment of Pax8 expression during pancreatic islet development and in human neuroendocrine tumors. Histochem Cell Biol 136, 595–607 (2011)

  • [66]LH. Tang, M. Gonen, C. Hedvat, IM Modlin, DS. Klimstra. Objective quantification of the Ki67 proliferative index in neuroendocrine tumors of the gastroenteropancreatic system: a comparison of digital image analysis with manual methods. Am J Surg Pathol 36, 1761-70 (2012)

  • [67]CM. McCall, C. Shi, TC. Cornish, DS. Klimstra, LH. Tang, O. Basturk, LJ. Mun, TA. Ellison, CL. Wolfgang, MA. Choti, RD. Schulick, BH. Edil, RH. Hruban. Grading of well-differentiated pancreatic neuroendocrine tumors is improved by the inclusion of both Ki67 proliferative index and mitotic rate. Am J Surg Pathol 37(11), 1671-7 (2013)

  • [68]Z. Yang, LH. Tang, M. Gonen, DS. Klimstra. Effect of tumor heterogeneity on the assessment of Ki67 labeling index in well-differentiated neuroendocrine tumors metastatic to the liver: implications for prognostic stratification. Am J Surg Pathol 35, 853-60 (2011)

  • [69]Z. Yang, LH. Tang, DS. Klimstra. How many needle core biopsies are needed to comfortably predict the histologic grade of metastatic well differentiated neuroendocrine tumors to the liver? Mod Pathol. 2012; 25:426A.

  • [70]L. Tang, J. Shia, E. Vakiani, et al. High grade trasformation of differentiated neuroendocrine neoplasms (NENs) of the enteropancreatic system-a unique entity distinct from de novo high grade neuroendocrine carcinoma (HGNECa) in pathogenesis and clinical behavior. Mod Pathology. 2008; 21:137A.

  • [71]FL. Vélayoudom-Céphise, P. Duvillard, L. Foucan, J. Hadoux, CN. Chougnet, S. Leboulleux, D. Malka, J. Guigay, D. Goere, T. Debaere, C. Caramella, M. Schlumberger, D. Planchard, D. Elias, M. Ducreux, JY. Scoazec, E. Baudin. Are G3 ENETS neuroendocrine neoplasms heterogeneous? End-Relat Cancer 29, 649-657 (2013).

  • [72]H. Sorbye, S. Welin, SW. Langer, LW. Vestermark, N. Holt, P. Osterlund, S. Dueland, E. Hofsli, M. G. Guren, MG. Guren, K. Ohrling, E. Birkemeyer, E. Thiis-Evensen, M. Biagini, H. Gronbaek, L. M. Soveri, I. H. Olsen, B. Federspiel, J. Assmus, E. T. Janson, U. Knigge. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal poorly differentiated neuroendocrine carcinoma: the NORDIC NEC study. J Clin Oncol 30 (2012)

  • [73]DS. Klimstra. Pathology Reporting of Neuroendocrine Tumors: Essential Elements for Accurate Diagnosis, Classification, and Staging. Seminars in Oncology 40, 23-36 (2013)

  • [74]G. Rindi. Clinicopathologic aspects of gastric neuroendocrine tumors.Am J Surg Pathol19, Suppl 1, S20-9 (1995)

  • [75]G. Rindi, C. Bordi, S. Rappel, S. La Rosa, M. Stolte, E. Solcia.Gastric carcinoids and neuroendocrine carcinomas: pathogenesis, pathology, and behavior.World J Surg 20(2), 168-72 (1996)

  • [76]G. Delle Fave, M. Marignani, VD. Corleto, S. Angeletti, G. D’Ambra, G. Ferraro, T. D’Adda, C. Azzoni, RT. Jensen, B. Annibale, C. Bordi. Progression of gastric enterochromaffin-like cells growth in Zollinger-Ellison syndrome and atrophic body gastritis patients. Dig Liver Dis 34(4), 270-8 (2002)

  • [77]G. Klöppel, M. Anlauf, A. Perren. Endocrine precursor lesions of gastroenteropancreatic neuroendocrine tumors. Endocr Pathol 18(3), 150-5 (2007)

  • [78]B. Annibale, C. Azzoni, VD. Corleto, E. Di Giulio, P. Caruana, G. D’Ambra, C. Bordi, G. Delle Fave. Atrophic body gastritis patients with enterochromaffin-like cell dysplasia are at increased risk for the development of type I gastric carcinoid.Eur J Gastroenterol Hepatol 13(12), 1449-56 (2001)

  • [79]A.Vanoli, S. La Rosa, O. Luinetti, C. Klersy, R. Manca, C. Alvisi, S. Rossi, E. Trespi, A. Zangrandi, F. Sessa, C. Capella, E. Solcia. Histologic changes in type A chronic atrophic gastritis indicating increased risk of neuroendocrine tumor development: the predictive role of dysplastic and severely hyperplastic enterochromaffin-like cell lesions. Hum Pathol 44(9), 1827-37 (2013)

  • [80]M. Anlauf, N. Garbrecht, J. Bauersfeld, A.Schmitt, T. Henopp, P. Komminoth, PU. Heitz, A. Perren, G. Klöppel.Hereditary neuroendocrine tumors of the gastroenteropancreatic system.Virchows Arch 451, Suppl 1, S29-38 (2007)

  • [81]DH.Hausman, RB. Weimann. Pulmonary tumorlet with hilar lymph node metastasis. Report of a case. Cancer 20(9), 1515-9 (1967)

  • [82]DR.Swarts, FC. Ramaekers, EJ. Speel.Molecular and cellular biology of neuroendocrine lung tumors: evidence for separate biological entities. Biochim Biophys Acta 1826(2), 255-71 (2012)

  • [83]JR.Gosney, IJ. Williams, AR. Dodson, CS. Foster.Morphology and antigen expression profile of pulmonary neuroendocrine cells in reactive proliferations and diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH).Histopathology 59(4), 751-62 (2011)

  • [84]J. Chan, and M. Kulke. Targeting the mTOR Signaling Pathway in Neuroendocrine Tumors. Curr Treat Options Oncol 15(3), 365–379 (2014)

  • [85]XM.Ma, J. Blenis. Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 10, 307-18 (2009)

  • [86]S.Wullschleger, R. Loewith, MN. Hall. TOR signaling in growth and metabolism.Cell. 10, 124(3):471-84 (2006)

  • [87]E. Jacinto, R. Loewith, A. Schmidt, S.Lin, MA. Rüegg, A. Hall, MN. Hall. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol6(11), 1122-8 (2004)

  • [88]CJ.Potter, LG. Pedraza, T. Xu. Akt regulates growth by directly phosphorylating Tsc2. Nat Cell Biol 4(9), 658-65 (2002)

  • [89]LF.Starker, T. Carling. Molecular genetics of gastroenteropancreatic neuroendocrine tumors. Curr Opin Oncol 21(1), 29-33 (2009)

  • [90]CM.Johannessen, EE. Reczek, MF. James, H. Brems, E. Legius, K. Cichowski.The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci USA 14, 8573-8 (2005)

  • [91]K.Öberg. The genetics of neuroendocrine tumors. Semin Oncol 40(1), 37-44 (2013)

  • [92]Y.Jiao, C. Shi, BH. Edil, RF. de Wilde, DS. Klimstra, A.Maitra, RD. Schulick, LH. Tang, CL. Wolfgang, MA. Choti, VE. Velculescu, LA. Jr Diaz, B. Vogelstein, KW. Kinzler, RH. Hruban, N. Papadopoulos. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 331, 1199-203 (2011)

  • [93]C.Roldo, E. Missiaglia, JP. Hagan, M.Falconi, P. Capelli, S. Bersani, GA. Calin, S. Volinia, CG. Liu, A. Scarpa, CM. Croce. MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J Clin Oncol 10, 4677-84 (2006)

  • [94]T.Gagliano, M. Bellio, E. Gentilin, D.Molè, F. Tagliati, M. Schiavon, NG. Cavallesco, LG. Andriolo, MR. Ambrosio, F. Rea, E. Degli Uberti, MC. Zatelli. mTOR, p70S6K, AKT, and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids.Endocr RelatCancer 24, 463-75 (2013)

  • [95]G.Rindi, C. Klersy, F. Inzani, G. Fellegara, L. Ampollini, A. Ardizzoni, N. Campanini, P. Carbognani, TM. De Pas, D. Galetta, PL. Granone, L. Righi, M. Rusca, L. Spaggiari, M. Tiseo, G. Viale, M. Volante, M. Papotti, G. Pelosi.Grading the neuroendocrine tumors of the lung: an evidence-based proposal. Endocr Relat Cancer16, 1-16 (2013)

  • [96]G. Pelosi, M. Papotti, G. Rindi, A. Scarpa. Unraveling tumor grading and genomic landscape in lung neuroendocrine tumors. Endocr Pathol 25, 151-64 (2014)

Article Metrics

  • Information

  • Download

  • Contents

Frontiers in Bioscience-Scholar (FBS) is published by IMR Press from Volume 13 Issue 1 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

1 Jan 2016Article

An update on the pathology of neuroendocrine tumors

Elia Guadagno 1, Marialaura Del Basso De Caro 1, Luigi Insabato 1,*
Affiliation
Article Info

1 Dept of Advanced Biomedical Sciences, Federico II University of Naples, Via Pansini 5, 80131 Naples, Italy

*Author to whom correspondence should be addressed.

 

Abstract

In this review, we highlight different aspects of a specialized tumor subset, neuroendocrine tumors. We discuss the terminology applied to these tumors, define their precancerous state, diagnostic criteria, immunohistochemical and molecular markers and finally the grading system that is currently applied to these subset of tumors.

Keywords

  • neuroendocrine
  • Ki67
  • pre-neoplastic lesions

References